Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Exp Neurol. 2020 Jan 16;326:113203. doi: 10.1016/j.expneurol.2020.113203

Figure 5:

Figure 5:

Effect of Mfsd2a overexpression on BWC and neurologic outcome at 24 hours following SBI

Effect of the administration of Mfsd2a CRISPR Act plasmid on BWC (A), mGarcia score (B), beam balance score (C) and percentage of foot faults (D) at 24 hours following SBI. SBI was associated with significantly increased BWC and neurologic dysfunction in all neurologic tests compared to the Sham group at 24 hours following the injury. The administration of Mfsd2a CRISPR Act at both doses of 2 μg and 4 μg decreased brain edema and improved performance in mGarcia score and left and total foot fault counts. Data are expressed as mean ± SD. n= 8/group. ANOVA, Tukey. **p<0.001 compared to Sham, *p<0.05 compared to Sham, ##p<0.001 compared to SBI, #p<0.05 compared to SBI, &&p<0.001 compared to SBI + Scramble CRISPR Act, &p<0.05 compared to SBI + Scramble CRISPR Act.

RF: right frontal, SBI: Surgical brain injury, LF: left frontal, RP: right parietal, LP: left parietal, C: cerebellum, BS: brainstem

HHS Vulnerability Disclosure